Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading Down 3.1% – What’s Next?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s stock price dropped 3.1% on Wednesday . The company traded as low as $27.40 and last traded at $27.40. Approximately 329,343 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 440,785 shares. The stock had previously closed at $28.29.

Wall Street Analyst Weigh In

Separately, Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a 50-day simple moving average of $30.78 and a 200-day simple moving average of $39.63. The stock has a market cap of $1.31 billion, a PE ratio of 9.19, a PEG ratio of 2.19 and a beta of 0.79.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. raised its stake in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after buying an additional 1,347,775 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company’s stock valued at $44,503,000 after purchasing an additional 105,288 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after purchasing an additional 14,015 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Amphastar Pharmaceuticals by 5.1% during the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock worth $22,767,000 after purchasing an additional 29,808 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.